Want to see ORIC full AI Analyst Report?
Top Page
Oric Pharmaceuticals
(NASDAQ:ORIC)
Select Model
Select Model
Rating:44Neutral
Price Target:
$8.50
▼(-38.54% Downside)
Action:Reiterated
Date:10/27/26
Overall score is weighed down primarily by continued lack of revenue, widening losses, and large negative free cash flow, despite a low-debt balance sheet. Technicals also remain bearish with the stock below key moving averages and negative MACD. Offsetting factors are limited but include positive pipeline progress toward a planned Phase 3 program, which supports longer-term upside if clinical results hold.
Positive Factors
Low leverage and financial flexibility
Minimal leverage reduces fixed financial obligations and gives ORIC greater flexibility to continue investing in its oncology pipeline. The sizable equity base provides a balance-sheet cushion for ongoing research, although continued losses could erode that flexibility over time.
Negative Factors
No revenue and widening losses
The absence of revenue means ORIC has not yet demonstrated commercial operating leverage, while widening losses indicate that spending continues to rise ahead of product sales. This leaves profitability dependent on successful clinical development and eventual commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage and financial flexibility
Minimal leverage reduces fixed financial obligations and gives ORIC greater flexibility to continue investing in its oncology pipeline. The sizable equity base provides a balance-sheet cushion for ongoing research, although continued losses could erode that flexibility over time.
Read all positive factors
Oric Pharmaceuticals (ORIC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$928.21M
Dividend YieldN/A
Average Volume (3M)1.56M
Price to Earnings (P/E)―
Beta (1Y)1.11
Revenue GrowthN/A
EPS Growth28.64%
CountryUS
Employees111
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.35
Shares Outstanding103,652,660
10 Day Avg. Volume1,364,620
30 Day Avg. Volume1,563,025
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)1.87
Price to Sales (P/S)0.00
P/FCF Ratio-6.30
Enterprise Value/Market Cap0.98
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.56K
Enterprise Value/Ebitda-6.35
Forecast
1Y Price Target
$23.56Price Target Upside70.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.5
Revenue Forecast (FY)N/A
Oric Pharmaceuticals Business Overview & Revenue Model
Company Description
ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage dr...
Oric Pharmaceuticals Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -584.00K | -1.22M | -1.11M | -1.03M | 0.00 | 0.00 |
| EBITDA | -143.01M | -128.25M | -126.74M | -99.67M | -85.80M | -77.82M |
| Net Income | -140.35M | -129.47M | -127.85M | -100.70M | -89.12M | -78.72M |
Balance Sheet | ||||||
| Total Assets | 404.69M | 411.00M | 274.14M | 254.69M | 250.36M | 298.64M |
| Cash, Cash Equivalents and Short-Term Investments | 264.76M | 281.49M | 255.96M | 208.19M | 206.27M | 236.98M |
| Total Debt | 3.33M | 11.55M | 3.18M | 10.21M | 12.10M | 1.93M |
| Total Liabilities | 23.43M | 26.64M | 31.02M | 30.60M | 28.01M | 25.67M |
| Stockholders Equity | 381.26M | 384.36M | 243.12M | 224.09M | 222.35M | 272.98M |
Cash Flow | ||||||
| Free Cash Flow | -112.42M | -114.08M | -113.85M | -86.54M | -77.22M | -60.48M |
| Operating Cash Flow | -111.64M | -113.37M | -112.66M | -85.69M | -75.14M | -59.54M |
| Investing Cash Flow | -99.66M | -148.03M | 22.14M | -43.40M | -109.25M | 158.44M |
| Financing Cash Flow | 172.92M | 245.26M | 126.55M | 85.66M | 25.23M | 49.13M |
Oric Pharmaceuticals Technical Analysis
Positive
13.83
Price Trends
12.95
Positive
11.73
Positive
11.15
Positive
Market Momentum
0.16
Negative
54.35
Neutral
75.59
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ORIC, the sentiment is Positive. The current price of 13.83 is above the 20-day moving average (MA) of 12.62, above the 50-day MA of 12.95, and above the 200-day MA of 11.15, indicating a bullish trend. The MACD of 0.16 indicates Negative momentum. The RSI at 54.35 is Neutral, neither overbought nor oversold. The STOCH value of 75.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ORIC.
Oric Pharmaceuticals Risk Analysis
Oric Pharmaceuticals disclosed 98 risk factors in its most recent earnings report. Oric Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Oric Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $1.46B | 7.23 | 2515.23% | ― | 92.92% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $1.12B | -5.45 | -41.49% | ― | ― | -63.70% | |
48 Neutral | $935.72M | -4.31 | -52.89% | ― | ― | 3.56% | |
44 Neutral | $928.21M | -6.63 | -35.35% | ― | ― | 28.64% | |
44 Neutral | $484.83M | -4.94 | -38.46% | ― | -87.03% | -179.91% |
* Healthcare Sector Average
ORIC
Oric Pharmaceuticals
8.96
-4.45
-33.17%
CTMX
CytomX Therapeutics
2.23
-1.13
-33.78%
ANAB
AnaptysBio
48.77
24.65
102.23%
CGEM
Cullinan Management
14.54
6.48
80.40%
BCAX
Bicara Therapeutics Inc.
16.89
-0.11
-0.65%
Oric Pharmaceuticals Corporate Events
Business Operations and StrategyProduct-Related Announcements
Oric Highlights Strong Enozertinib Data, Eyes Phase 3
Positive
Oct 23, 2026
On October 23, 2026, Oric Pharmaceuticals presented updated Phase 1b data for enozertinib in first-line EGFR atypical non-small cell lung cancer at the ESMO Congress, highlighting strong systemic and intracranial efficacy in a high-risk population...
Business Operations and StrategyRegulatory Filings and Compliance
Oric Pharmaceuticals Expands Inducement Equity Incentive Plan
Positive
Jul 30, 2026
On July 28, 2026, ORIC Pharmaceuticals’ board approved an amended and restated 2022 Inducement Equity Incentive Plan, increasing the shares of common stock reserved for issuance to an aggregate of 3,350,000. The plan, adopted without stockho...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.